ScreenerHero

DMAC DiaMedica Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · diamedica.com
7.760USD-2.88%Mkt Cap: 430.87M $P/E: —

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinan…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap430.87M USD
Enterprise Value395.10M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-32.77M USD
Revenue/Share—
Last Price7.760 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.06
PEG—
EV/EBITDA-10.09
EV/Revenue—
P/S—
P/B11.43
EPS (TTM)-0.72
EPS (Forward)-0.81
52W Range
5.24549% of range10.42
52W High10.42 USD
52W Low5.245 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-58.39%
ROA-53.39%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.06M USD
CapEx (TTM)40.00K USD
FCF Margin—
FCF Yield-4.10%
Net Debt-43.32M USD
Net Debt/EBITDA1.11
Balance Sheet
Debt/Equity0.00
Current Ratio6.72
Quick Ratio6.63
Book Value/Sh0.71 USD
Cash/Share0.81 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateNov 15, 2018
Splits
Last Split1:20
Split DateNov 15, 2018
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.50 USD
Upside (mean)+99.7%
Target Range11.00 USD – 25.00 USD
11.00+99.7% to mean25.00
# Analysts4
Ownership
Shares Out.53.93M
Float25.30M
Insiders27.83%
Institutions40.91%
Short Interest
Short Ratio41.2d
Short % Float15.16%
Short % Out.10.17%
Shares Short5.49M
Short (prev mo.)5.36M
Technical
SMA 506.925 (+12.1%)
SMA 2007.097 (+9.3%)
Beta0.91
S&P 52W Chg16.45%
Avg Vol (30d)190.10K
Avg Vol (10d)254.61K
Technical Indicators
RSI (14)59.7
MACD0.4048
MACD Signal0.3646
MACD Hist.+0.0402
BB Upper9.041 USD
BB Middle7.514 USD
BB Lower5.987 USD
BB Width40.63%
ATR (14)0.4385 USD
Vol Ratio (20d)1.01x